|Back to article|
Vaccine - HPV; Immunization - HPV; Gardasil; Cervarix; HPV2; HPV4; Vaccine to prevent cervical cancer
HPV is a common virus that is spread through sexual contact. There are many different types of HPV. Many types do not cause problems. But certain types of HPV can lead to:
Two vaccines called HPV2 (Cervarix) and HPV4 (Gardasil) are approved:
These vaccines do not treat cervical cancer.
WHO SHOULD GET THIS VACCINE
HPV4 (Gardasil) is approved for:
HPV2 (Cervarix) is approved for:
Girls ages 11 and 12 should receive the HPV vaccine series:
Girls and women ages 13 to 26:
Boys ages 11 to 12 should receive the HPV4 (Gardasil) vaccine series:
Boys and men ages 13 to 21:
Men ages 22 to 26:
Pregnant women should not receive this vaccine. But there have been no problems found in women who received the vaccine during pregnancy, before they knew they were pregnant.
The most common side effects are fainting, dizziness, nausea, headache, and skin reactions at the site where the shot was given.
WHAT ELSE TO THINK ABOUT
The HPV vaccine does not protect against all types of HPV that lead to cervical cancer. Girls and women should still receive regular screening (Pap smear) to look for early signs of cervical cancer.
The HPV vaccine does not protect against other infections that can be spread during sexual contact.
CALL YOUR HEALTH CARE PROVIDER IF
American Academy of Pediatrics, Committee on Infectious Diseases. Policy Statement: HPV vaccine recommendations. Pediatrics. 2012. DOI: 10.1542/peds.2011-3865.
Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedules for Persons Aged 0 Through 18 Years and Adults Aged 19 Years and Older — United States, 2013. MMWR. 2013;62(Suppl1):1-19.
Kahn JA. HPV vaccination for the prevention of cervical intraepithelial neoplasia. N Engl J Med. 2009;361:271-278.
Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009 Aug 19;302(7):750-757.
Reviewed by:Susan Storck, MD, FACOG, Chief, Eastside Department of Obstetrics and Gynecology, Group Health Cooperative of Puget Sound, Bellevue, Washington; Clinical Teaching Faculty, Department of Obstetrics and Gynecology, University of Washington School of Medicine. Also reviewed by A.D.A.M. Health Solutions, Ebix, Inc., Editorial Team: David Zieve, MD, MHA, Bethanne Black, Stephanie Slon, and Nissi Wang.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorousstandards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information andservices. Learn more about A.D.A.M.'s editorialpolicy, editorialprocess, and privacypolicy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch.)
The information provided herein should not be used during any medical emergency or for the diagnosis or treatmentof any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions.Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 2014 A.D.A.M., Inc. Any duplication ordistribution of the information contained herein is strictly prohibited.